Impact of infective versus sterile transvenous lead removal on 30-day outcomes in cardiac implantable electronic devices. Posted on April 12th, 2024 by LEADconnection GoTo Clinical Trial Post navigation Previous: Pacing and Defibrillation Consideration in the Era of Transcatheter Tricuspid Valve Replacement.Next: Leadless Pacemaker Implantation from the Jugular Vein Ipsilateral to the Dialysis Catheter: Last Resort for Patients with Limited Vascular Routes.
Pacing and Defibrillation Consideration in the Era of Transcatheter Tricuspid Valve Replacement. Posted on April 12th, 2024 by LEADconnection GoTo Clinical Trial Post navigation Previous: Effects of envelopes on cardiac implantable electronic device pocket healing: A head-to-head preclinical evaluation.Next: Impact of infective versus sterile transvenous lead removal on 30-day outcomes in cardiac implantable electronic devices.
Effects of envelopes on cardiac implantable electronic device pocket healing: A head-to-head preclinical evaluation. Posted on April 12th, 2024 by LEADconnection GoTo Clinical Trial Post navigation Previous: Transvenous lead extraction safety and efficacy in infected and noninfected patients using mechanical-only tools: Prospective registry from a high-volume centerNext: Pacing and Defibrillation Consideration in the Era of Transcatheter Tricuspid Valve Replacement.